In addition, there is now increasing scientific interest in the effects of newer anti-hyperglycemic agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, in patients with NAFLD or NASH, as these agents may not only exert hepatoprotective actions but also have a marked benefit on cardiovascular and renal outcomes, regardless of the presence or absence of T2D [15,34,109,125]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.